Abstract
This study is an audit and a comparison of major infective complications in patients with granulomatosis with polyangiitis (GPA) and systemic lupus erythematosis (SLE). Data were collected on consecutive patients attending a single treatment approach, multidisciplinary vasculitis centre who met diagnostic criteria for GPA and SLE from 01/01/2006 to 30/06/2006. Immunosuppressive treatment is used in this clinic with guidelines targeting avoidance of neutropenia. For each patient, documentation was made of disease presentation, organ involvement and therapy used. A history of major infections requiring hospital admission and intravenous antimicrobials pre- and post-diagnosis was recorded. Patients with GPA received a higher cumulative dose of cyclophosphamide, had a higher median age, shorter period of follow-up and had lower mean and nadir absolute lymphocyte counts and nadir neutrophil counts. GPA patients had more major infections per patient years (P = 0.0027) and respiratory tract infections (P = 0.0031) per patient years. Relative risk (RR) of major infection was significantly increased with methylprednisolone, RR 11.1 (P = <0.0001), cyclophosphamide, RR 2.0 (P = 0.0246) and the intensive phase of treatment, RR 13.3 (P = <0.0001). Marked lymphopenia was common in both groups during follow-up and was associated with an increased risk of major infection (P = 0.0020). Major infections, in particular respiratory tract infections, are more common in those treated for GPA than SLE. This may be due to a combination of factors including greater doses and duration of methyprednisolone and cyclophosphamide. We recommend treatment strategies that aim not only to avoid neutropenia but that also identify lymphopenia as a risk factor for major infection.
Similar content being viewed by others
References
Johnson AE, Gordon C, Palmer RG, Bacon PA (1995) The prevalence and incidence of systemic lupus erythematosus in Birmingham, England. Relationship to ethnicity and country of birth. Arthr Rheum 38:551–558
Patel M, Clarke AM, Bruce IN, Symmons DP (2006) The prevalence and incidence of biopsy-proven lupus nephritis in the UK: evidence of an ethnic gradient. Arthr Rheum 54:2963–2969
Dhaygude A, Bruce IN, O’Donoghue D et al (2007) Incidence of biopsy proven pauci-immune necrotising/crescentic glomerulonephritis in Greater Manchester. J Am Soc Nephrol 18:FP0995
Watts RA, Lane SE, Bentham G, Scott DG (2000) Epidemiology of systemic vasculitis: a ten-year study in the United Kingdom. Arthr Rheum 43:414–419
Falk RJ, Gross WL, Guillevin L et al (2011) Granulomatosis with polyangiitis (Wegener’s): an alternative name for Wegener’s granulomatosis. Ann Rheum Dis 70:704
Bolton WK, Sturgill BC (1989) Methylprednisolone therapy for acute crescentic rapidly progressive glomerulonephritis. Am J Nephrol 9:368–375
Pagnoux C, Hogan SL, Chin H et al (2008) Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis: comparison of two independent cohorts. Arthr Rheum 58:2908–2918
Jayne DR, Gaskin G, Rasmussen N et al (2007) Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 18:2180–2188
Ruiz-Irastorza G, Olivares N, Ruiz-Arruza I, Martinez-Berriotxoa A, Egurbide MV, Aguirre C (2009) Predictors of major infections in systemic lupus erythematosus. Arthr Res Ther 11:R109
Gescuk BD, Davis JC Jr (2002) Novel therapeutic agents for systemic lupus erythematosus. Curr Opin Rheumatol 14:515–521
Illei GG, Austin HA, Crane M et al (2001) Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med 135:248–257
Jayne D (2000) Evidence-based treatment of systemic vasculitis. Rheumatology (Oxford) 39:585–595
Austin HA III, Klippel JH, Balow JE et al (1986) Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 314:614–619
Cohen J, Pinching AJ, Rees AJ, Peters DK (1982) Infection and immunosuppression. A study of the infective complications of 75 patients with immunologically-mediated disease. Q J Med 51:1–15
Houssiau FA, Vasconcelos C, D’Cruz D et al (2002) Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthr Rheum 46:2121–2131
Guillevin L, Cordier JF, Lhote F et al (1997) A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener’s granulomatosis. Arthr Rheum 40:2187–2198
Charlier C, Henegar C, Launay O et al (2009) Risk factors for major infections in Wegener granulomatosis: analysis of 113 patients. Ann Rheum Dis 68:658–663
Jallouli M, Frigui M, Marzouk S, Maaloul I, Kaddour N, Bahloul Z (2008) Infectious complications in systemic lupus erythematosus: a series of 146 patients. Rev Med Interne 29:626–631
Pagnoux C, Cohen P, Hamidou M et al (2005) Treatment of ANCA-associated vasculitides: corticosteroids and pulse cyclophosphamide followed by maintenance therapy with methotrexate or azathioprine: a prospective multicenter randomized trial (WEGENT). American College of Rheumatology, 69th annual scientific meeting, San Diego. Arthr Rheum 52
de Groot K, Harper L, Jayne DR et al (2009) Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med 150:670–680
Sinclair A, Appel G, Dooley MA et al (2007) Mycophenolate mofetil as induction and maintenance therapy for lupus nephritis: rationale and protocol for the randomized, controlled Aspreva Lupus Management Study (ALMS). Lupus 16:972–980
Bradley JD, Brandt KD, Katz BP (1989) Infectious complications of cyclophosphamide treatment for vasculitis. Arthr Rheum 32:45–53
Booth AD, Almond MK, Burns A et al (2003) Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study. Am J Kidney Dis 41:776–784
Jarrousse B, Guillevin L, Bindi P et al (1993) Increased risk of Pneumocystis carinii pneumonia in patients with Wegener’s granulomatosis. Clin Exp Rheumatol 11:615–621
Krafcik SS, Covin RB, Lynch JP III, Sitrin RG (1996) Wegener’s granulomatosis in the elderly. Chest 109:430–437
Falagas ME, Manta KG, Betsi GI, Pappas G (2007) Infection-related morbidity and mortality in patients with connective tissue diseases: a systematic review. Clin Rheumatol 26:663–670
Morgan BP, Walport MJ (1991) Complement deficiency and disease. Immunol Today 12:301–306
Foster CB, Lehrnbecher T, Mol F et al (1998) Host defense molecule polymorphisms influence the risk for immune-mediated complications in chronic granulomatous disease. J Clin Invest 102:2146–2155
Keeling DM, Isenberg DA (1993) Haematological manifestations of systemic lupus erythematosus. Blood Rev 7:199–207
Nived O, Sturfelt G, Wollheim F (1985) Systemic lupus erythematosus and infection: a controlled and prospective study including an epidemiological group. Q J Med 55:271–287
Nossent JC, Swaak AJ (1991) Prevalence and significance of haematological abnormalities in patients with systemic lupus erythematosus. Q J Med 80:605–612
Higgins RM, Goldsmith DJ, Connolly J et al (1996) Vasculitis and rapidly progressive glomerulonephritis in the elderly. Postgrad Med J 72:41–44
Hunder GG, Arend WP, Bloch DA et al (1990) The American College of Rheumatology 1990 criteria for the classification of vasculitis. Introduction. Arthr Rheum 33:1065–1067
Jennette JC, Falk RJ, Andrassy K et al (1994) Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthr Rheum 37:187–192
Lapraik C, Watts R, Bacon P et al (2007) BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis. Rheumatology (Oxford) 46:1615–1616
Little MA, Nightingale P, Verburgh CA et al (2010) Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis. Ann Rheum Dis 69:1036–1043
Gibson KL, Gipson DS, Massengill SA et al (2009) Predictors of relapse and end stage kidney disease in proliferative lupus nephritis: focus on children, adolescents, and young adults. Clin J Am Soc Nephrol 4:1962–1967
Dhaygude A, Griffith M, Cairns T, McLean A, Palmer A, Taube D (2004) Prolonged treatment with low-dose intravenous pulse cyclophosphamide may reduce rate of relapse in ANCA-associated vasculitis. Nephron Clin Pract 97:c154–c159
De’Oliviera J, Gaskin G, Dash A, Rees AJ, Pusey CD (1995) Relationship between disease activity and anti-neutrophil cytoplasmic antibody concentration in long-term management of systemic vasculitis. Am J Kidney Dis 25:380–389
Pilheu JA, De Salvo MC, Gonzalez J, Rey D, Elias MC, Ruppi MC (1997) CD4+ T-lymphocytopenia in severe pulmonary tuberculosis without evidence of human immunodeficiency virus infection. Int J Tuberc Lung Dis 1:422–426
Goupil R, Nadeau-Fredette A, Troyanov S, Brachemi S (2010) Severe lymphopenia is frequent and predictive of infectious complications in ANCA vasculitis. American Society of Nephrology Renal Week, Denver
Stanford E, Print F, Falconer M et al (2009) Immune response to pneumococcal conjugate vaccination in asplenic individuals. Hum Vaccin 5:85–91
Conflict of interest
No financial support was received by any author in relation to the work in this manuscript, and none of the authors have any financial interests which could create a potential conflict of interest or the appearance of a conflict of interest with regard to the work.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Morton, M., Edmonds, S., Doherty, A.M. et al. Factors associated with major infections in patients with granulomatosis with polyangiitis and systemic lupus erythematosus treated for deep organ involvement. Rheumatol Int 32, 3373–3382 (2012). https://doi.org/10.1007/s00296-011-2151-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00296-011-2151-0